BioSpace News Archive

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that an article highlighting preclinical data from BT7480, a Bicycle tumor-targeted immune cell agonist® (Bicycle TICA™) targeting Nectin-4 and agonizing CD137 (4-1BB), was published in the Journal of Medicinal Chemistry.

According to Vision Research Reports, the global metaverse in healthcare market size was valued at USD 5.5 billion in 2021 and is expected to worth around USD 75.8 billion by 2030 with a CAGR of 36% from 2022 to 2030.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $28 million of procurement orders for oral TPOXX® (tecovirimat).

According to a Vision Research Reports, the global Membrane Oxygenators market size is expected to be worth around US$ 241.5 Mn by 2030.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2022 financial results will be released on Tuesday, August 2, after the market closes.

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM).

According to Vision Research Reports, the global Point Of Care Ultrasound Systems market size is expected to be worth around US$ 2.7 billion by 2030.

According to Vision Research Reports, the global therapeutic respiratory devices market was surpassed at USD 10.2 billion in 2021 and is expected to hit around USD 16.3 billion by 2030, growing at a CAGR of 5.35% from 2022 to 2030.

The global X-ray systems market size was valued at USD 5.7 billion in 2020, and is predicted to hit around USD 9.6 billion by 2030, registering a CAGR of 2.4% during the forecast period 2022 to 2030.

According to latest report study, the global respiratory virus infection drugs market reached value at US$ 38.8 Bn in 2020 and predicted to hit around US$ 82.1 billion by 2030, expanding at a CAGR of 7.1% from 2021 to 2030.